CME Information
Title:
Mechanical Circulatory Devices: Contemporary Long-Term Management
Faculty:
Joseph G. Rogers, MD, FACC, FHFSA (Chair)
Professor of Medicine, Division of Cardiology
Medical Director, Cardiac Transplant and Mechanical Circulatory Support Program
Duke University
Durham, NC
Mandeep R. Mehra, MD , FACC, FESC, FHSFA, FRCP
Professor of Medicine, Harvard Medical School
Medical Director, Brigham and Women’s Hospital Heart and Vascular Center
Executive Director, Collaborative Center for Advanced Heart Disease
Boston, MA
Petar M. Seferovic, MD, PhD, FACC, FESC
Chair of Internal Medicine, University of Belgrade School of Medicine
Professor, Heart Failure Center, Belgrade University Medical Center
President, Heart Failure Society of Serbia
President, Heart Failure Association of the ESC
Belgrade, Serbia
Mark S. Slaughter, MD
Professor of Surgery
Chair, Department of Cardiovascular and Thoracic Surgery
University of Louisville School of Medicine
Executive Medical Director, Cardiovascular Services, Heart Transplant and Mechanical Assist Devices
University of Louisville/Jewish Hospital
Louisville, KY
Mary Norine Walsh, MD, MACC, FHFSA
Medical Director, Heart Failure and Cardiac Transplantation
St. Vincent Heart Center
Immediate Past President, American College of Cardiology
Indianapolis, IN
Credit Hours: 1.5
Program Description:
Mechanically assisted circulation has been established as an evidenced-based and increasingly important option for patients with Stage D heart failure failing optimal medical and electrical therapies. There is a broad range of knowledge about the therapy as implementation has primarily been limited to large academic centers with associated transplant programs. However, the growth of the therapy has resulted in heightened patient awareness about assisted circulation as well as the strong likelihood that these patients are being seen in healthcare facilities away from implanting centers. This program addresses several of the issues above by providing knowledge regarding assisted circulation for both less-experienced clinicians and those with greater levels of expertise.
Program Developer/Facilitator:
Heart Failure Society of America
Target Audience:
Heart failure clinicians and cardiologists who care for patients with HF.
Learning Objectives:
Following this activity, participants will be able to:
- Identify key components of the ESC/HFA position statement on ventricular assist devices.
- Compare and contrast the ESC/HFA position with the US perspective.
- Outline the challenges in identifying and selecting patients for advanced therapies.
- Discuss the reported outcomes from ventricular assist devices over the past decade.
- Define the process for evaluating patients who might qualify for both VAD and transplant therapies.
- Discuss current and future challenges in evaluating patients for long-term mechanical circulatory support.
Disclosures:
It is our policy to ensure balance, independence, objectivity, and scientific rigor in all of our educational programs. Faculty and course directors have disclosed relevant financial relationships with commercial companies, and HFSA has a process in place to resolve any conflict of interest.
Joseph Rogers, MD, FACC, FHFSA indicated he has nothing to disclose.
Mary Walsh, MD, FACC, FHFSA indicated she has nothing to disclose.
Mandeep Mehra, MD, FACC, FESC, FRCP indicated the following relationships:
- Consultant/Advisory Board for Abbott, Medtronic, Janssen, Mesoblast, Portola, NupulseCV, Bayer
Mark Slaughter, MD indicated he has nothing to disclose.
Petar Seferovic, MD indicated the following relationships:
- Research Grant from Novartis
- Speaker Honoraria from Berlin Chemie Menarini, Servier, Richter Gedeon, Novartis
HFSA staff involved in the development and review of this activity have nothing to disclose.
Faculty members are required to inform the audience when they are discussing off-label or unapproved uses of devices or drugs. Devices or drugs that are still undergoing clinical trials are identified as such and should not be portrayed as standard, accepted therapy. Please consult full prescribing information before using any product mentioned in this activity. If using products in an investigational, off-label manner, it is the responsibility of the prescribing physician to monitor the medical literature to determine recommended dosages and uses of the drugs. Neither the publisher nor the providers promote the use of any agent outside of approved labeling.
Accreditation Statement:
The Heart Failure Society of America is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement:
The Heart Failure Society of America designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This continuing nursing education activity was approved by the Ohio Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. (OBN-001-91)
This activity is approved for 1.5 contact hours.
Approval through 09/05/2020; ONA #21891
Commercial Support Statement:
Supported by independent medical education grants from the Amyloidosis Research Consortium and Pfizer
Certificate Fee:
$0.00
Disclaimer:
The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions; the publisher; Heart Failure Society of America; the Amyloidosis Research Consortium or Pfizer. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.